EA200800422A1 - Способы лечения заболеваний, обусловленных химическими веществами - Google Patents
Способы лечения заболеваний, обусловленных химическими веществамиInfo
- Publication number
- EA200800422A1 EA200800422A1 EA200800422A EA200800422A EA200800422A1 EA 200800422 A1 EA200800422 A1 EA 200800422A1 EA 200800422 A EA200800422 A EA 200800422A EA 200800422 A EA200800422 A EA 200800422A EA 200800422 A1 EA200800422 A1 EA 200800422A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- sub
- phenyl
- alkyl
- group
- methods
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000000126 substance Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 238000011260 co-administration Methods 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 239000011630 iodine Substances 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cephalosporin Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Настоящее изобретение относится к способу профилактики, лечения или улучшения заболеваний, обусловленных химическими веществами, включающему введение субъекту, нуждающемуся в этом, эффективного количества соединения, выбранного из формулы (I), или формулы (II), или их фармацевтически пригодных форм, в котором фенил замещен по положению Х от одного до пяти атомами галогена, выбранными из группы, включающей фтор, хлор, бром и йод; и R, R, R, R, Rи Rнезависимо выбраны из группы, включающей в себя водород и C-Cалкильную группу; где C-Cалкильная группа необязательно замещена фенильной группой (причем фенильная группа необязательно замещена заместителями, независимо выбранными из группы, содержащей галогеновую, C-Cалкильную, C-Cалкокси-, амино-, нитро- и цианогруппу). Дополнительно способы включают в себя совместное введение соединений изобретения с одним или более соединениями, для которых известно, что они лечат заболевания, обусловленные химическими веществами.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2005/026439 WO2007018496A1 (en) | 2005-07-26 | 2005-07-26 | Methods for treating substance-related disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200800422A1 true EA200800422A1 (ru) | 2008-10-30 |
| EA019935B1 EA019935B1 (ru) | 2014-07-30 |
Family
ID=35064669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200800422A EA019935B1 (ru) | 2005-07-26 | 2005-07-26 | Способы лечения алкогольной абстиненции |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1928451B1 (ru) |
| JP (1) | JP5094720B2 (ru) |
| KR (1) | KR101199499B1 (ru) |
| CN (1) | CN101272776B (ru) |
| AT (1) | ATE538784T1 (ru) |
| AU (1) | AU2005335241B9 (ru) |
| BR (1) | BRPI0520451A2 (ru) |
| CA (1) | CA2616721C (ru) |
| EA (1) | EA019935B1 (ru) |
| ES (1) | ES2385087T3 (ru) |
| IL (1) | IL189003A0 (ru) |
| NO (1) | NO20080877L (ru) |
| WO (1) | WO2007018496A1 (ru) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0613697A2 (pt) | 2005-06-08 | 2011-01-25 | Sk Holdings Co Ltd | tratamento de distúrbios de sono-vigìlia |
| KR102173587B1 (ko) | 2009-06-22 | 2020-11-04 | 에스케이바이오팜 주식회사 | 피로의 치료 또는 예방 방법 |
| US8232315B2 (en) * | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| EP2496227B1 (en) | 2009-11-06 | 2019-05-22 | SK Biopharmaceuticals Co., Ltd. | Methods for treating fibromyalgia syndrome |
| KR101783632B1 (ko) | 2009-11-06 | 2017-10-10 | 에스케이바이오팜 주식회사 | 주의력 결핍/과잉행동 장애(ａｄｈｄ)의 치료 방법 |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
| WO2014164969A1 (en) | 2013-03-13 | 2014-10-09 | Aerial Biopharma, Llc | Treatment of cataplexy |
| WO2015010014A1 (en) | 2013-07-18 | 2015-01-22 | Jazz Pharmaceuticals International Iii Limited | Treatment for obesity |
| US10195151B2 (en) | 2016-09-06 | 2019-02-05 | Jazz Pharmaceuticals International Iii Limited | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
| WO2018222954A1 (en) | 2017-06-02 | 2018-12-06 | Jazz Pharmaceuticals International Iii Limited | Methods and compositions for treating excessive sleepiness |
| CN114096314A (zh) * | 2019-06-27 | 2022-02-25 | 沼泽敏彦 | 痴呆症的治疗和预防药 |
| US10940133B1 (en) | 2020-03-19 | 2021-03-09 | Jazz Pharmaceuticals Ireland Limited | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3313692A (en) * | 1958-04-21 | 1967-04-11 | Armour Pharma | Method of inducing calming and muscle relaxation with carbamates |
| ES2291454T3 (es) * | 2001-02-27 | 2008-03-01 | Ortho-Mcneil Pharmaceutical, Inc. | Utilizacion de carbamatos para prevenir o tratar trastornos del movimiento. |
| US6541513B2 (en) * | 2001-02-27 | 2003-04-01 | Ortho-Mcneil Pharmaceutical, Inc. | Carbamate compounds for use in preventing or treating psychotic disorders |
| JP4276839B2 (ja) * | 2001-02-27 | 2009-06-10 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 双極性障害の予防もしくは治療における使用のためのカルバメート化合物 |
| CA2439295C (en) * | 2001-02-27 | 2010-05-25 | Ortho-Mcneil Pharmaceutical, Inc. | Carbamate compounds for use in preventing or treating neurodegenerative disorders |
| US20070021500A1 (en) * | 2005-07-12 | 2007-01-25 | Twyman Roy E | Methods for neuroprotection |
-
2005
- 2005-07-26 CN CN200580051664XA patent/CN101272776B/zh not_active Expired - Fee Related
- 2005-07-26 AT AT05775692T patent/ATE538784T1/de active
- 2005-07-26 ES ES05775692T patent/ES2385087T3/es not_active Expired - Lifetime
- 2005-07-26 AU AU2005335241A patent/AU2005335241B9/en not_active Ceased
- 2005-07-26 JP JP2008523847A patent/JP5094720B2/ja not_active Expired - Fee Related
- 2005-07-26 BR BRPI0520451-8A patent/BRPI0520451A2/pt not_active Application Discontinuation
- 2005-07-26 KR KR1020087004533A patent/KR101199499B1/ko not_active Expired - Lifetime
- 2005-07-26 WO PCT/US2005/026439 patent/WO2007018496A1/en not_active Ceased
- 2005-07-26 CA CA2616721A patent/CA2616721C/en not_active Expired - Lifetime
- 2005-07-26 EA EA200800422A patent/EA019935B1/ru not_active IP Right Cessation
- 2005-07-26 EP EP05775692A patent/EP1928451B1/en not_active Expired - Lifetime
-
2008
- 2008-01-24 IL IL189003A patent/IL189003A0/en unknown
- 2008-02-19 NO NO20080877A patent/NO20080877L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20080877L (no) | 2008-02-19 |
| CA2616721A1 (en) | 2007-02-15 |
| CA2616721C (en) | 2014-01-21 |
| KR101199499B1 (ko) | 2012-11-09 |
| JP2009502914A (ja) | 2009-01-29 |
| BRPI0520451A2 (pt) | 2009-05-12 |
| AU2005335241A1 (en) | 2007-02-15 |
| CN101272776B (zh) | 2012-10-03 |
| AU2005335241B2 (en) | 2012-11-15 |
| EA019935B1 (ru) | 2014-07-30 |
| CN101272776A (zh) | 2008-09-24 |
| WO2007018496A1 (en) | 2007-02-15 |
| EP1928451A1 (en) | 2008-06-11 |
| ES2385087T3 (es) | 2012-07-18 |
| JP5094720B2 (ja) | 2012-12-12 |
| ATE538784T1 (de) | 2012-01-15 |
| KR20080037055A (ko) | 2008-04-29 |
| IL189003A0 (en) | 2008-11-03 |
| EP1928451B1 (en) | 2011-12-28 |
| AU2005335241B9 (en) | 2012-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20080877L (no) | Fremgangsmater for behandling av substansrelaterte forstyrrelser | |
| NO20071921L (no) | Fremgangsmater for behandling av epileptogenese og epilepsi | |
| ECSP088179A (es) | Compuestos de carbamato para usarse en el tratamiento de desordenes neurodegenerativos | |
| BR0207831A (pt) | Compostos carbamato para uso na prevenção ou tratamento de distúrbios do movimento | |
| MY138156A (en) | Carbamate compounds for use in preventing or treating neurodegenerative disorders | |
| PT1408953E (pt) | Compostos carbamato para utilizacao na prevencao ou tratamento do disturbio bipolar | |
| DE60223506D1 (de) | Carbamatverbindungen zur vorbeugung oder behandlung bipolarer erkrankungen | |
| BR0207673A (pt) | Compostos de carbamato para o uso no tratamento de dor | |
| DE60210960D1 (de) | Carbamat-verbindungen zur prävention oder behandlung von angstzuständen | |
| EA200800295A1 (ru) | Способы лечения эпилептогенеза | |
| MX2009004553A (es) | Metodos para el tratamiento de trastornos cocleares y vestibulares. | |
| BR0207829A (pt) | Composto de carbamato para uso na prevenção ou tratamento de distúrbios psicóticos | |
| MY149385A (en) | Methods for treating substance-related disorders | |
| NO20040176L (no) | Karbamatforbindelser for anvendelse ved prevensjon eller terapi av neuropatisk smerte og kluster- og migrenehodepineassosiert smerte | |
| MY136733A (en) | Carbamate compounds for use in preventing or treating psychotic disorders | |
| TW200701978A (en) | Methods of treating epileptogenesis and epilepsy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
| PC4A | Registration of transfer of a eurasian patent by assignment |